CN112804999B - 通过异丁司特治疗眼科疾病/病症或损伤的方法 - Google Patents

通过异丁司特治疗眼科疾病/病症或损伤的方法 Download PDF

Info

Publication number
CN112804999B
CN112804999B CN201980066306.8A CN201980066306A CN112804999B CN 112804999 B CN112804999 B CN 112804999B CN 201980066306 A CN201980066306 A CN 201980066306A CN 112804999 B CN112804999 B CN 112804999B
Authority
CN
China
Prior art keywords
day
ibudilast
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980066306.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN112804999A (zh
Inventor
松田和子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of CN112804999A publication Critical patent/CN112804999A/zh
Application granted granted Critical
Publication of CN112804999B publication Critical patent/CN112804999B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980066306.8A 2018-10-19 2019-10-18 通过异丁司特治疗眼科疾病/病症或损伤的方法 Active CN112804999B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748148P 2018-10-19 2018-10-19
US62/748,148 2018-10-19
PCT/US2019/056948 WO2020081941A1 (en) 2018-10-19 2019-10-18 Methods of treating ophthalmic disease/disorder or injury with ibudilast

Publications (2)

Publication Number Publication Date
CN112804999A CN112804999A (zh) 2021-05-14
CN112804999B true CN112804999B (zh) 2024-03-15

Family

ID=68503211

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980066306.8A Active CN112804999B (zh) 2018-10-19 2019-10-18 通过异丁司特治疗眼科疾病/病症或损伤的方法

Country Status (7)

Country Link
US (1) US11154540B2 (https=)
EP (1) EP3866788B1 (https=)
JP (1) JP7430719B2 (https=)
CN (1) CN112804999B (https=)
CA (1) CA3116577A1 (https=)
ES (1) ES2970996T3 (https=)
WO (1) WO2020081941A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12005049B2 (en) 2021-07-26 2024-06-11 Medicinova, Inc. Methods of preventing cancer metastasis
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101355876A (zh) * 2005-11-09 2009-01-28 康宾纳特克斯公司 治疗医学病症的方法、组合物和药剂盒
CN101848712A (zh) * 2007-07-11 2010-09-29 美迪诺亚公司 用异丁地特治疗渐进性神经变性疾病
CN104411678A (zh) * 2012-05-04 2015-03-11 奥克塞拉有限公司 用于治疗糖尿病性视网膜病及其他眼科疾病的方法
CN107205986A (zh) * 2014-11-26 2017-09-26 美迪诺亚公司 异丁司特和利鲁唑的组合及其使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395747B1 (en) 1998-08-10 2002-05-28 Sauro Sakoda Remedies for multiple sclerosis
JP4954085B2 (ja) 2004-12-06 2012-06-13 メディシノバ， インコーポレイテッド 神経障害性疼痛及びその関連する症状を治療するためのイブジラスト
WO2008119500A1 (en) * 2007-03-30 2008-10-09 Fovea Pharmaceuticals Sa Methods for treating neovascular ocular diseases
IN2014MN01552A (https=) * 2012-02-27 2015-05-08 Rohto Pharma

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101355876A (zh) * 2005-11-09 2009-01-28 康宾纳特克斯公司 治疗医学病症的方法、组合物和药剂盒
CN101848712A (zh) * 2007-07-11 2010-09-29 美迪诺亚公司 用异丁地特治疗渐进性神经变性疾病
CN104411678A (zh) * 2012-05-04 2015-03-11 奥克塞拉有限公司 用于治疗糖尿病性视网膜病及其他眼科疾病的方法
CN107205986A (zh) * 2014-11-26 2017-09-26 美迪诺亚公司 异丁司特和利鲁唑的组合及其使用方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis";Robert J. Fox et al.;《Contemporary Clinical Trials》;第50卷;第166-177页 *
"The glial cell modulator ibudilast attenuates neuroinflammation and enhances retinal ganglion cell viability in glaucoma through protein kinase A signaling";Jorge L. Cueva Vargas et al.;《Neurobiology of Disease》;第93卷;第156-171页 *
林丁等主编.常见眼科疾病防治265问》.湖南科学技术出版社,2016,第97页. *
韩杰等主编.《当代神经系统疾病概论》.辽宁科学技术出版社,2014,第354页. *

Also Published As

Publication number Publication date
CA3116577A1 (en) 2020-04-23
EP3866788A1 (en) 2021-08-25
US11154540B2 (en) 2021-10-26
WO2020081941A1 (en) 2020-04-23
CN112804999A (zh) 2021-05-14
ES2970996T3 (es) 2024-06-03
JP2022505184A (ja) 2022-01-14
EP3866788B1 (en) 2023-12-13
US20200121659A1 (en) 2020-04-23
JP7430719B2 (ja) 2024-02-13

Similar Documents

Publication Publication Date Title
US20250073213A1 (en) Treatment of progressive neurodegenerative disease with ibudilast
CN112804999B (zh) 通过异丁司特治疗眼科疾病/病症或损伤的方法
CN118139619A (zh) 异丁司特以联合治疗方式用于治疗胶质母细胞瘤
EP3863628B1 (en) Combination of ibudilast and interferon-beta and methods of using same
HK1147953A (en) Treatment of progressive neurodegenerative disease with ibudilast

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant